Novel Gemini vitamin D3 analogs have potent antitumor activity
- 30 November 2008
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 112 (1-3) , 151-156
- https://doi.org/10.1016/j.jsbmb.2008.09.012
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathwayThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogsThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Vitamin D compounds in leukemiaThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Anti-tumor activity of calcitriol: pre-clinical and clinical studiesThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cellsBlood, 2001
- Highly active analogs of 1α,25-dihydroxyvitamin D3 that resist metabolism through C-24 oxidation and C-3 epimerization pathwaysSteroids, 2001
- Alterations of differentiation, clonal proliferation, cell cycle progression and bcl-2 expression in RARα-altered sublines of HL-60Leukemia, 1997
- Mutations of the p16 gene product are rare in prostate cancerThe Prostate, 1997
- Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calciumCancer Letters, 1995
- Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogensBiochemistry and Cell Biology, 1994